Samuel Ryu1, Stephanie L Pugh2, Peter C Gerszten3, Fang-Fang Yin4, Robert D Timmerman5, Ying J Hitchcock6, Benjamin Movsas7, Andrew A Kanner8, Lawrence B Berk9, David S Followill10, Lisa A Kachnic11. 1. Henry Ford Hospital, Detroit, Michigan. Electronic address: sryu1@hfhs.org. 2. RTOG Statistical Center, Philadelphia, Pennsylvania. 3. University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. 4. Duke University Medical Center, Durham, North Carolina. 5. University of Texas Southwestern, Dallas, Texas. 6. Huntsman Cancer Center, University of Utah, Salt Lake City, Utah. 7. Henry Ford Hospital, Detroit, Michigan. 8. Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel. 9. H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida. 10. University of Texas MD Anderson Cancer Center, Houston, Texas. 11. Boston Medical Center Minority-Based Community Clinical Oncology Program, Boston, Massachusetts.
Abstract
PURPOSE: The phase 2 component of Radiation Therapy Oncology Group (RTOG) 0631 assessed the feasibility and safety of spine radiosurgery (SRS) for localized spine metastases in a cooperative group setting. METHODS AND MATERIALS: Patients with 1-3 spine metastasis with a Numerical Rating Pain Scale (NRPS) score ≥5 received 16 Gy single fraction SRS. The primary endpoint was SRS feasibility: image guidance radiation therapy (IGRT) targeting accuracy ≤2 mm, target volume coverage >90% of prescription dose, maintaining spinal cord dose constraints (10 Gy to ≤10% of the cord volume from 5-6 mm above to 5-6 mm below the target or absolute spinal cord volume <0.35 cc) and other normal tissue dose constraints. A feasibility success rate <70% was considered unacceptable for continuation of the phase 3 component. Based on the 1-sample exact binomial test with α = 0.10 (1-sided), 41 patients were required. Acute toxicity was assessed using the National Cancer Institute Common Toxicity Criteria for Adverse Events, version 3.0. RESULTS: Sixty-five institutions were credentialed with spine phantom dosimetry and IGRT compliance. Forty-six patients were accrued, and 44 were eligible. There were 4 cervical, 21 thoracic, and 19 lumbar sites. Median NRPS was 7 at presentation. Final pretreatment rapid review was approved in 100%. Accuracy of image guided SRS targeting was in compliance with the protocol in 95%. The target coverage and spinal cord dose constraint were in accordance with the protocol requirements in 100% and 97%. Overall compliance for other normal tissue constraints was per protocol in 74%. There were no cases of grade 4-5 acute treatment-related toxicity. CONCLUSIONS: The phase 2 results demonstrate the feasibility and accurate use of SRS to treat spinal metastases, with rigorous quality control, in a cooperative group setting. The planned RTOG 0631 phase 3 component will proceed to compare pain relief and quality of life between SRS and external beam radiation therapy.
PURPOSE: The phase 2 component of Radiation Therapy Oncology Group (RTOG) 0631 assessed the feasibility and safety of spine radiosurgery (SRS) for localized spine metastases in a cooperative group setting. METHODS AND MATERIALS: Patients with 1-3 spine metastasis with a Numerical Rating Pain Scale (NRPS) score ≥5 received 16 Gy single fraction SRS. The primary endpoint was SRS feasibility: image guidance radiation therapy (IGRT) targeting accuracy ≤2 mm, target volume coverage >90% of prescription dose, maintaining spinal cord dose constraints (10 Gy to ≤10% of the cord volume from 5-6 mm above to 5-6 mm below the target or absolute spinal cord volume <0.35 cc) and other normal tissue dose constraints. A feasibility success rate <70% was considered unacceptable for continuation of the phase 3 component. Based on the 1-sample exact binomial test with α = 0.10 (1-sided), 41 patients were required. Acute toxicity was assessed using the National Cancer Institute Common Toxicity Criteria for Adverse Events, version 3.0. RESULTS: Sixty-five institutions were credentialed with spine phantom dosimetry and IGRT compliance. Forty-six patients were accrued, and 44 were eligible. There were 4 cervical, 21 thoracic, and 19 lumbar sites. Median NRPS was 7 at presentation. Final pretreatment rapid review was approved in 100%. Accuracy of image guided SRS targeting was in compliance with the protocol in 95%. The target coverage and spinal cord dose constraint were in accordance with the protocol requirements in 100% and 97%. Overall compliance for other normal tissue constraints was per protocol in 74%. There were no cases of grade 4-5 acute treatment-related toxicity. CONCLUSIONS: The phase 2 results demonstrate the feasibility and accurate use of SRS to treat spinal metastases, with rigorous quality control, in a cooperative group setting. The planned RTOG 0631 phase 3 component will proceed to compare pain relief and quality of life between SRS and external beam radiation therapy.
Authors: Andrea Molineu; David S Followill; Peter A Balter; William F Hanson; Michael T Gillin; M Saiful Huq; Avraham Eisbruch; Geoffrey S Ibbott Journal: Int J Radiat Oncol Biol Phys Date: 2005-10-01 Impact factor: 7.038
Authors: Peter C Gerszten; Steven A Burton; William C Welch; Adam M Brufsky; Barry C Lembersky; Cihat Ozhasoglu; William J Vogel Journal: Cancer Date: 2005-11-15 Impact factor: 6.860
Authors: William F Hartsell; Charles B Scott; Deborah Watkins Bruner; Charles W Scarantino; Robert A Ivker; Mack Roach; John H Suh; William F Demas; Benjamin Movsas; Ivy A Petersen; Andre A Konski; Charles S Cleeland; Nora A Janjan; Michelle DeSilvio Journal: J Natl Cancer Inst Date: 2005-06-01 Impact factor: 13.506
Authors: Peter C Gerszten; Steven A Burton; Cihat Ozhasoglu; William J Vogel; William C Welch; Joseph Baar; David M Friedland Journal: J Neurosurg Spine Date: 2005-10
Authors: Matthew M Gestaut; Nitika Thawani; Sangroh Kim; Veera R Gutti; Sameer Jhavar; Niloyjyoti Deb; Andrew Morrow; Russell A Ward; Jason H Huang; Mehul Patel Journal: J Neurooncol Date: 2017-04-13 Impact factor: 4.130
Authors: Roman O Kowalchuk; Michael R Waters; K Martin Richardson; Kelly Spencer; James M Larner; Jason P Sheehan; William H McAllister; Charles R Kersh Journal: J Radiosurg SBRT Date: 2020
Authors: Elizabeth M Jaffee; Chi Van Dang; David B Agus; Brian M Alexander; Kenneth C Anderson; Alan Ashworth; Anna D Barker; Roshan Bastani; Sangeeta Bhatia; Jeffrey A Bluestone; Otis Brawley; Atul J Butte; Daniel G Coit; Nancy E Davidson; Mark Davis; Ronald A DePinho; Robert B Diasio; Giulio Draetta; A Lindsay Frazier; Andrew Futreal; Sam S Gambhir; Patricia A Ganz; Levi Garraway; Stanton Gerson; Sumit Gupta; James Heath; Ruth I Hoffman; Cliff Hudis; Chanita Hughes-Halbert; Ramy Ibrahim; Hossein Jadvar; Brian Kavanagh; Rick Kittles; Quynh-Thu Le; Scott M Lippman; David Mankoff; Elaine R Mardis; Deborah K Mayer; Kelly McMasters; Neal J Meropol; Beverly Mitchell; Peter Naredi; Dean Ornish; Timothy M Pawlik; Jeffrey Peppercorn; Martin G Pomper; Derek Raghavan; Christine Ritchie; Sally W Schwarz; Richard Sullivan; Richard Wahl; Jedd D Wolchok; Sandra L Wong; Alfred Yung Journal: Lancet Oncol Date: 2017-10-31 Impact factor: 41.316
Authors: Manuel Valdivieso; Benjamin W Corn; Janet E Dancey; D Lawrence Wickerham; L Elise Horvath; Edith A Perez; Alison Urton; Walter M Cronin; Erica Field; Evonne Lackey; Charles D Blanke Journal: Semin Oncol Date: 2015-07-10 Impact factor: 4.929
Authors: Kelly C Younge; Robin B Marsh; Dawn Owen; Huaizhi Geng; Ying Xiao; Daniel E Spratt; Joseph Foy; Krithika Suresh; Q Jackie Wu; Fang-Fang Yin; Samuel Ryu; Martha M Matuszak Journal: Int J Radiat Oncol Biol Phys Date: 2018-01-04 Impact factor: 7.038
Authors: Benjamin Spieler; Stuart E Samuels; Ricardo Llorente; Raphael Yechieli; John Chetley Ford; Eric A Mellon Journal: Pract Radiat Oncol Date: 2019-11-26